Valentin Fuster, MD, PhD, president of Mount Sinai Heart and physician-in-chief of the Mount Sinai Hospital in New York City, said the trial was the first to show a therapy could prevent secondary adverse cardiovascular events in people who have previously had a heart attack, according to a news release.
The pill, which is approved in 25 countries but not the U.S., is composed of three active ingredients: acetylsalicylic acid, atorvastatin and ramipril. Its maker has submitted a drug approval application to the FDA.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
